For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
The current state of pharmaceutical tariffs
Background Amid the Trump trade upheaval, pharmaceutical products receive different treatment than many other US imports. Pharmaceuticals are treated differently for reasons such as their…
DC Journal
Point: Medicaid Work Requirements Are a Common-Sense Reform
Medicaid is the government program that is supposed to help the poor afford health care. Its cost to taxpayers has skyrocketed in the last few…
Blog
Congress considers micromanaging PBM finances
With the first reconciliation bill behind it, Congress is now looking to reform other aspects of the health care system. Pharmacy Benefit Manager (PBM)…
Search Posts
Comment
Letter to OIRA Re: Request for OIRA to Resolve Interagency Disagreement Concerning IQA Implementation About Medical Marijuana
The Competitive Enterprise Institute (CEI) requests that OIRA resolve a dispute between two different agencies concerning responsibility for ensuring compliance with the Information Quality Act.
The New York Post
Politicians Are Using Omicron as an Excuse to Return to their Autocratic Ways
Since the start of the pandemic, governors around the country have often struggled to appear to be doing something to stem COVID-19, regardless of whether…
City Journal
One Size Doesn’t Fit All
In a rebuke of the Biden administration, the Fifth Circuit Court of Appeals reaffirmed its stay of the Occupational Safety and Health Administration’s (OSHA) workplace…
The New York Post
A Reality Check on How we Handle COVID-19 Risks
COVID-19 is still with us. Cases are rising in Europe and to a smaller extent in this country. But the fact that SARS-CoV-2, the virus…
Letters
CEI Joins ATR Led Drug Price Control Coalition Letter
Dear Member of Congress: We write in opposition to the Democrat plan to impose price controls, a 95 percent excise tax, and inflation penalties on…
National Review
What’s Taking the FDA So Long on COVID Drug Molnupiravir?
On October 1, pharmaceutical companies Merck and Ridgeback Biotherapeutics announced that their investigational oral antiviral drug Molnupiravir reduced the risk of hospitalization or death…
